JPWO2020186132A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020186132A5 JPWO2020186132A5 JP2021555282A JP2021555282A JPWO2020186132A5 JP WO2020186132 A5 JPWO2020186132 A5 JP WO2020186132A5 JP 2021555282 A JP2021555282 A JP 2021555282A JP 2021555282 A JP2021555282 A JP 2021555282A JP WO2020186132 A5 JPWO2020186132 A5 JP WO2020186132A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- patient
- hae
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002888A JP2025061116A (ja) | 2019-03-14 | 2025-01-08 | 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818189P | 2019-03-14 | 2019-03-14 | |
| US62/818,189 | 2019-03-14 | ||
| PCT/US2020/022535 WO2020186132A1 (en) | 2019-03-14 | 2020-03-13 | Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002888A Division JP2025061116A (ja) | 2019-03-14 | 2025-01-08 | 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525164A JP2022525164A (ja) | 2022-05-11 |
| JPWO2020186132A5 true JPWO2020186132A5 (enExample) | 2023-03-20 |
Family
ID=70228815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021555282A Pending JP2022525164A (ja) | 2019-03-14 | 2020-03-13 | 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 |
| JP2025002888A Pending JP2025061116A (ja) | 2019-03-14 | 2025-01-08 | 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002888A Pending JP2025061116A (ja) | 2019-03-14 | 2025-01-08 | 遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200317815A1 (enExample) |
| EP (1) | EP3938404A1 (enExample) |
| JP (2) | JP2022525164A (enExample) |
| KR (1) | KR20210142006A (enExample) |
| AU (1) | AU2020237259A1 (enExample) |
| CA (1) | CA3133576A1 (enExample) |
| MX (1) | MX2021011110A (enExample) |
| TW (1) | TW202100561A (enExample) |
| WO (1) | WO2020186132A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
| PT3096798T (pt) | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| CN116077648A (zh) | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| MX2022008649A (es) | 2020-01-13 | 2022-09-23 | Takeda Pharmaceuticals Co | Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico. |
| WO2022156798A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| PT3096798T (pt) * | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| CN116077648A (zh) * | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
-
2020
- 2020-03-13 EP EP20718034.0A patent/EP3938404A1/en active Pending
- 2020-03-13 TW TW109108355A patent/TW202100561A/zh unknown
- 2020-03-13 US US16/817,671 patent/US20200317815A1/en active Pending
- 2020-03-13 JP JP2021555282A patent/JP2022525164A/ja active Pending
- 2020-03-13 CA CA3133576A patent/CA3133576A1/en active Pending
- 2020-03-13 MX MX2021011110A patent/MX2021011110A/es unknown
- 2020-03-13 KR KR1020217033056A patent/KR20210142006A/ko active Pending
- 2020-03-13 WO PCT/US2020/022535 patent/WO2020186132A1/en not_active Ceased
- 2020-03-13 AU AU2020237259A patent/AU2020237259A1/en active Pending
-
2025
- 2025-01-08 JP JP2025002888A patent/JP2025061116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022033868A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2003531129A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| JPWO2020186132A5 (enExample) | ||
| KR20240117655A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| TW202321303A (zh) | 抗pla2r自體抗體媒介膜性腎病變之治療 | |
| JPWO2020047352A5 (enExample) | ||
| RU2021129732A (ru) | Ингибиторы плазменного калликреина и их применение для лечения приступа наследственного ангионевротического отека | |
| JPWO2021146160A5 (enExample) | ||
| JPWO2022231978A5 (enExample) | ||
| WO2019182333A1 (ko) | 항-vegfr-2 항체 | |
| JPWO2021243002A5 (enExample) | ||
| JPWO2021127525A5 (enExample) | ||
| JPWO2020128864A5 (enExample) | ||
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| JPWO2021252835A5 (enExample) | ||
| HK40102408B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| HK40102408A (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| CN118076640A (zh) | 抗-pla2r自身抗体介导的膜性肾病的治疗 | |
| CN118974082A (zh) | 通过使用抗c5抗体可伐利单抗用于治疗或预防格林-巴利综合征的剂量及施用方案 | |
| RU2022129376A (ru) | Комбинированный лекарственный препарат для лечения рака почек |